Jim Tananbaum is the founder of Foresite Capital. Foresite Capital is a company which provides growth capital to different healthcare leaders that are emerging with different disruptive products as well as services. These products and services are across all of the healthcare sectors in not only public markets but also private markets. Tananbaum has led investments in many different healthcare companies. Before this, he founded as well as held different positions in management at a pharmaceutical company.
Tananbaum has his Medical Degree from Harvard Medical School. He also holds an M.B.A. from the Business School located at Harvard. His Bachelors of Science Degree came from Yale University. In addition to his education as well as his career experience, Jim Tananbaum also has served on Harvard’s MIT-HST program’s advisory board as well as their visiting committee. He also performed these tasks for the Yale School of Engineering.
Foresite Capital is an equity firm that focuses of healthcare growth. They recently announced Molly He as a new venture partner. He formerly was the senior director at a company known as Illumina and spent more than 15 years working in pharmaceutical and genomic development as well as research. As one of the most respected researchers of all things scientific, Jim Tananbaum was thrilled to have her join the team.
While working at Illumina, He was responsible for all of the improvements as well as the innovation of Illumina’s global protein reagent. Before this, she worked for Pacific Biosciences as their head of protein sciences. Here she was also responsible for the company’s protein reagent development in addition in addition to their real-time sequencing chemistry.
According to Ideamensch, during an earlier time of her career, He had experience in the pharmaceutical industry where she was focused on the structural-based design of small molecule drugs as well as antibody drugs that both targeted cancer and also different immune diseases. Her bachelor’s degree is in biochemistry and came from Nankai University. She also holds a Ph.D. from the University of California, Los Angeles, which is focused in protein biophysics. She has authored more than 20 papers that have all been published. She also has more than 20 different patent applications as well as issued patents. These are all in the field of personalized medicine as well as next-generation sequencing. More details can be found on his LinkedIn account.